The size of the global market for Alzheimer's therapeutics was estimated at USD 4.04 billion in 2021, and it is anticipated to grow at a CAGR of 16.2% from 2022 to 2030. Market expansion is anticipated to be fueled by the increasing prevalence of Alzheimer's disease and the approval of disease-modifying treatments. Alzheimer's disease was present in about 6.2 million Americans 65 and older in 2021; by 2060, that number is expected to rise to about 13.8 million. Due to their longer life expectancy, women are more likely than men to be diagnosed with Alzheimer's disease. Additionally, Alzheimer's disease is quickly over taking other neurodegenerative diseases as the leading cause of death and a major contributor to physical impairment that calls for urgent medical attention.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
